AVEO PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2001-01-01

Employees: 115

Market Cap: -

Website: http://www.aveooncology.com

Clinical Trials

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Tivozanib

First Posted Date: 2011-02-16

Last Posted Date: 2020-10-27

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 105

Registration Number: NCT01297244

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States

and more 22 locations

A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: tivozanib

First Posted Date: 2010-09-29

Last Posted Date: 2011-09-26

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 50

Registration Number: NCT01210846

Locations: 🇺🇸
Associates in Oncology/Hematology, Rockville, Maryland, United States
🇺🇸
Tennessee Onocology, Nashville, Tennessee, United States
🇺🇸
Oklahoma University Cancer Institute (OUCI), Oklahoma City, Oklahoma, United States

and more 5 locations

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

Phase 3

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: Sorafenib
Drug: Tivozanib

First Posted Date: 2010-02-25

Last Posted Date: 2020-10-05

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 277

Registration Number: NCT01076010

Locations: 🇨🇱
Site 122, Santiago, Chile
🇷🇴
Site 441, Bucharest, Romania
🇺🇦
Site 496, Donetsk, Ukraine

and more 72 locations

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
Carcinoma, Non-Small Cell-Lung
Respiratory Tract Neoplasms
Lung Neoplasms

Interventions: Biological: AV-299 + gefitinib
Drug: Gefitinib

First Posted Date: 2009-12-25

Last Posted Date: 2015-04-08

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 203

Registration Number: NCT01039948

Locations: 🇹🇭
Investigational Site 24, Chiang Mai, Thailand
🇵🇭
Investigational Site 14, Quezon City, Philippines
🇹🇭
Investigational Site 23, Bangkok, Thailand

and more 23 locations

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

Phase 3

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: tivozanib (AV-951)
Drug: Sorafenib

First Posted Date: 2009-12-11

Last Posted Date: 2019-10-28

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 517

Registration Number: NCT01030783

Locations: 🇮🇳
Site 155, Jaipur, Rajasthan, India
🇮🇳
Site 191, Jaipur, Rajasthan, India
🇮🇳
Site 152, Vellore, Tamil Nadu, India

and more 83 locations

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

Phase 1

Completed

Conditions: Malignant Solid Tumour
Liver Metastases

Interventions: Biological: AV-299

First Posted Date: 2009-09-01

Last Posted Date: 2012-04-12

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 19

Registration Number: NCT00969410

Locations: 🇪🇸
Investigational Site 1, Barcelona, Spain

An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Tivozanib (AV-951)

First Posted Date: 2009-01-22

Last Posted Date: 2012-06-28

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 17

Registration Number: NCT00826878

Locations: 🇺🇸
Kansas University Medical Center, Kansas City, Kansas, United States
🇺🇸
Memorial Sloan-Kettering, New York, New York, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

Phase 1

Completed

Conditions: Lymphomas
Malignant Solid Tumor
Multiple Myeloma

Interventions: Biological: AV-299
Biological: AV-299 + erlotinib

First Posted Date: 2008-07-30

Last Posted Date: 2014-01-27

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 41

Registration Number: NCT00725634

Locations: 🇺🇸
Investigational Site 2, Scottsdale, Arizona, United States
🇺🇸
Investigational Site 3, Columbus, Ohio, United States
🇺🇸
Investigational Site 1, San Antonio, Texas, United States

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: tivozanib (AV-951) + paclitaxel

First Posted Date: 2008-07-17

Last Posted Date: 2012-06-28

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT00717340

Locations: 🇺🇸
Dana Farber Cancer Institute, Inc., Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇩🇪
Universitaetsklinikum Essen, Essen, Germany

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Phase 1

Completed

Conditions: Colorectal Cancer
Gastrointestinal Cancer

Interventions: Drug: Tivozanib (AV-951) plus FOLFOX6

First Posted Date: 2008-04-17

Last Posted Date: 2012-08-28

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT00660153

Locations: 🇳🇱
Erasmus Medical Center; Department of Medical Oncology, Rotterdam, Netherlands
🇳🇱
University Medical Center Groningen; Internal Medicine, Department of Medical Oncology, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy